Grufity logoGrufity logo

ABBV

163.72USD-0.22(-0.13%)Market Closed

AbbVie Inc

Market Summary

USD163.72-0.22Market Closed
-0.13%

ABBV Stock Price

RSI Chart

Valuation

Market Cap

261.0B

Price/Earnings

20.65

Price/Sales

4.55

Price/Cashflow

11.39

MarketCap/EBT

18.55

Price/Sales

Profitability

EBT Margin

24.54%

Return on Equity

86.24%

Return on Assets

8.83%

Fundamentals

Revenue

Revenue (TTM)

57.8B

Revenue Y/Y

3.28%

Revenue Q/Q

1.57%

Earnings

Earnings (TTM)

13.4B

Earnings Y/Y

24.22%

Earnings Q/Q

327.38%

Price Action

52 Week Range

116.22171.07
(Low)(High)

Last 7 days

3.5%

Last 30 days

12.7%

Last 90 days

19.2%

Trailing 12 Months

40.2%

Financial Health

Current Ratio

0.84

Debt/Equity

4.16

Debt/Cashflow

0.38

Investor Care

Dividend Yield

3.95%

Dividend/Share (TTM)

5.64

Shares Dilution (1Y)

0.03%

Diluted EPS (TTM)

7.49

Peers (Alternatives to AbbVie)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
12.69% 40.17%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
1.16% -37.31%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.98% 19.60%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.97% 52.06%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.42% 24.09%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
4.50% 46.57%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
15.89% 47.00%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-1.99% 2.32%
-18.85
63.29
26.15% -23.38%
3.8B
-
13.27% -45.82%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
15.45% -49.16%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
11.20% -50.29%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
17.07% 137.52%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
- -14.14%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
2.53% -63.72%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-2.84% -83.50%
-0.46
19.11
-77.61% 5.14%

Financials for AbbVie

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue0.8%57,81957,34956,72556,19755,169
  S&GA Expenses1.5%15,10314,88212,63412,34912,320
Earnings Before Taxes5.1%14,78314,07114,05112,9897,211
Net Income6.1%13,40712,63712,47911,5427,534
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-1.3%141,325143,186143,211146,529148,858
  Current Assets4.3%30,36429,10026,50927,92828,957
    Cash Equivalents38.9%11,8328,5216,0989,74612,182
  Inventory-6.6%3,1723,3963,4833,1283,094
  Net PPE-1.3%4,8934,9585,0755,1105,130
  Goodwill-0.9%31,72632,02832,29832,37932,296
  Current Liabilities-5.1%32,71234,47332,52135,19428,533
.    Short Term Borrowings-41.2%1017121416
  Long Term Debt-1.0%60,39961,00263,52275,96274,049
Shareholder's Equity9.2%15,99414,65316,28315,40813,550
  Retained Earnings40.9%4,9533,5165,1033,1271,600
  Additional Paid-In Capital0.8%19,05618,90618,73118,30518,108
Accumulated Depreciation-5,617----
Shares Outstanding-0.1%1,7701,7711,770--
Minority Interest-5.7%3335312827
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-1.5%22,59022,92322,80822,77722,556
  Share Based Compensation-1.3%668677729692699
Cashflow From Investing59.0%-1,320.00-3,221.00-3,593.00-2,344.00-1,826.00
Cashflow From Financing-9.6%-21,507.00-19,632.00-22,837.00-19,039.00-16,396.00
  Dividend Payments2.0%9,8519,6629,4659,2619,048
  Buy Backs-0.1%1,6141,6161,6179341,099

Risks

What is the probability of a big loss on ABBV?

68.5%


Probability that AbbVie stock will be more than 20% underwater in next one year

7.7%


Probability that AbbVie stock will be more than 30% underwater in next one year.

0%


Probability that AbbVie stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABBV drawdown profile look like?

Y-axis is the maximum loss one would have experienced if AbbVie was unfortunately bought at previous high price.

Returns

Cumulative Returns on ABBV

21.6%


7-Year Cumulative Returns

17.0%


5-Year Cumulative Returns

29.3%


3-Year Cumulative Returns

What are the long-term rolling returns for ABBV?

FIve years rolling returns for AbbVie.

Which funds bought or sold ABBV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
SALEM CAPITAL MANAGEMENT INC
UNCHANGED
-
-36,000
255,000
0.20%
2022-11-23
Aurora Investment Counsel
SOLD OFF
-100
-425,000
-
-%
2022-11-23
Invst, LLC
REDUCED
-5.25
-108,000
1,435,000
0.25%
2022-11-23
FSB PREMIER WEALTH MANAGEMENT, INC.
ADDED
0.18
-31,000
225,000
0.13%
2022-11-23
Toroso Investments, LLC
ADDED
6.78
-681,000
9,913,000
0.41%
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-2.48
-262,833
1,543,000
0.95%
2022-11-22
IHT Wealth Management, LLC
ADDED
16.9
161,000
6,769,000
0.51%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
77,414,000
77,414,000
0.91%
2022-11-22
Mint Tower Capital Management B.V.
NEW
-
538,000
538,000
0.04%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
ADDED
6,303.02
17,058,000
17,347,000
0.64%

1–10 of 45

Latest Funds Activity

Are funds buying ABBV calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ABBV

AbbVie News

Seeking Alpha

How We Beat The S&P 500 By 25% Year To Date With Dividend Stocks.8 hours ago

The Motley Fool

Yahoo Finance

ABBV Fair Value

Recent SEC filings of AbbVie

View All Filings
Date Filed Form Type Document
Nov 29, 2022
8-K
Current Report
Nov 04, 2022
10-Q
Quarterly Report
Nov 04, 2022
S-8
Employee Benefits Plan
Oct 28, 2022
8-K
Current Report
Oct 27, 2022
3
Insider Trading
Oct 20, 2022
UPLOAD
UPLOAD
Oct 17, 2022
8-K
Current Report
Oct 14, 2022
8-K
Current Report
Oct 05, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for ABBV

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-05-23
SEVERINO MICHAEL
SOLD
-12,041,800
150.898
-79,801
Vice Chairman
2022-05-23
SEVERINO MICHAEL
ACQUIRED
8,697,630
108.991
79,801
Vice Chairman
2022-05-17
SEVERINO MICHAEL
SOLD
-15,404,400
154.044
-100,000
Vice Chairman
2022-05-17
SEVERINO MICHAEL
ACQUIRED
8,837,930
88.3793
100,000
Vice Chairman
2022-05-16
Gosebruch Henry O
SOLD
-13,013,800
155
-83,960
EVP, Chief Strategy Officer
2022-05-16
Gosebruch Henry O
ACQUIRED
4,606,050
54.86
83,960
EVP, Chief Strategy Officer
2022-05-16
SEVERINO MICHAEL
ACQUIRED
6,650,280
66.5028
100,000
Vice Chairman
2022-05-16
SEVERINO MICHAEL
SOLD
-15,445,100
154.451
-100,000
Vice Chairman

1–10 of 50

Richard A. Gonzalez
50000
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Income Statement

2022-09-30
Condensed Consolidated Statements of Earnings (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Net revenues$ 14,812$ 14,342$ 42,933$ 41,311
Cost of products sold5,0224,39013,24413,126
Selling, general and administrative3,3043,08311,8439,089
Research and development1,6141,6614,7205,095
Acquired IPR&D and milestones40402454719
Other operating expense, net22950057432
Total operating costs and expenses10,20910,03630,31828,461
Operating earnings4,6034,30612,61512,850
Interest expense, net4975851,5681,813
Net foreign exchange loss361210835
Other expense (income), net(330)214272,284
Earnings before income tax expense4,4003,68810,5128,718
Income tax expense4485081,1391,214
Net earnings3,9523,1809,3737,504
Net earnings attributable to noncontrolling interest31106
Net earnings attributable to AbbVie Inc.$ 3,949$ 3,179$ 9,363$ 7,498
Per share data    
Basic earnings per share (in dollars per share)$ 2.22$ 1.78$ 5.26$ 4.21
Diluted earnings per share (in dollars per share)$ 2.21$ 1.78$ 5.24$ 4.19
Weighted-average basic shares outstanding (in shares)1,7711,7701,7711,769
Weighted-average diluted shares outstanding (in shares)1,7761,7771,7771,776

ABBV Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets  
Cash and equivalents$ 11,832$ 9,746
Short-term investments4784
Accounts receivable, net10,7439,977
Inventories3,1723,128
Prepaid expenses and other4,5704,993
Total current assets30,36427,928
Investments235277
Property and equipment, net4,8935,110
Intangible assets, net68,72575,951
Goodwill31,72632,379
Other assets5,3824,884
Total assets141,325146,529
Current liabilities  
Short-term borrowings1014
Current portion of long-term debt and finance lease obligations9,19712,481
Accounts payable and accrued liabilities23,50522,699
Total current liabilities32,71235,194
Long-term debt and finance lease obligations60,39964,189
Deferred income taxes1,9723,009
Other long-term liabilities30,21528,701
Commitments and contingencies
Stockholders' equity  
Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,973,038 shares issued as of September 30, 2022 and 1,803,195,293 as of December 31, 20211818
Common stock held in treasury, at cost, 44,572,117 shares as of September 30, 2022 and 34,857,597 as of December 31, 2021(4,590)(3,143)
Additional paid-in capital19,05618,305
Retained earnings4,9533,127
Accumulated other comprehensive loss(3,443)(2,899)
Total stockholders' equity15,99415,408
Noncontrolling interest3328
Total equity16,02715,436
Total liabilities and equity$ 141,325$ 146,529